Intellia Therapeutics Enters Into $400M Non-Dilutive Senior Secured Term Loan Facility With OrbiMed
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that it has entered into a
Intellia borrowed $400 million from a lender to help pay for their work on medicine, without giving up ownership of the company. This means they have cash to keep going, which is helpful to watch when you see how long companies can keep developing new treatments.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.